- Location
G protein coupled receptor
"-
Trevena Announced Today Initiation of Dosing in BLAST-AHF
Jan 10, 2014Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center ...
Tags: Trevena, GPCR biased ligands, BLAST-AHF, acute heart failure
-
The Study Was Published Online in Nature Chemistry on DEC. 15.
Jan 2, 2014Roughly 40 percent of all medications act on cells' G protein-coupled receptors (GPCRs). One of these receptors, beta 2 adrenergic receptor site (B2AR), naturally transforms between two base configurations; knowing the precise location of ...
Tags: G protein-coupled receptors, beta 2 adrenergic receptor site
-
New Technique Is a Major Advance in Exploring GPCRs
Jan 2, 2014Researchers have used one of the brightest X-ray sources on the planet to map the 3-D structure of an important cellular gatekeeper known as a G protein-coupled receptor, or GPCR, in a more natural state than possible before. The new ...
-
Ono Pharmaceuticals Has Elected to Amend and Expand The Existing Collaboration Agreement
Dec 12, 2013Receptos, a biopharmaceutical company, has announced that Ono Pharmaceuticals has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor ...
Tags: Pharmaceuticals, Receptos
-
Heptares Supplies Delivered The First Stabilised G Protein-Coupled Receptor to Morphosys
Oct 12, 2013US-based drug discovery and development firm, Heptares Therapeutics has delivered the first stabilised G protein-coupled receptor (GPCR) called 'StaR' to MorphoSys for antibody discovery as part of their antibody therapeutics alliance. ...
Tags: Heptares Therapeutics, drug
-
UCB Has Signed a Research Deal with ConfometRx for The Discovery of New Drugs
Feb 26, 2013Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs. Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor ...
Tags: drug discovery, biopharmaceutical, UCB